タケウチ　ツトム   TAKEUCHI Tsutomu   竹内　勤    所属   埼玉医科大学  医学部 学長室    職種   学長
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patents with rheumatoid arthritis: Post-hoc analysis of clinical trials
掲載誌名	正式名：International Journal of Rheumatic Disease 略　 称：IJRD
掲載区分	国外
出版社	Weily
巻・号・頁	26(7),1248-1259頁
著者・共著者	Tanaka Y, Takeuchi T, Haaland D, Hall S, Inanc N, Li Z, Xavier RM, Cara C, Tilt N, and Taylor PC
発行年月	2023/05/17
概要	Aim: Elevated rheumatoid factor (RF) level has been associated with RA disease progression and poorer TNFi response. We assessed the efficacy of CZP in patients with early and established RA across baseline RF levels. Results: Overall, 316, 1537, and 908 patients were included in C-OPERA, pooled RAPID trials, and EXXELERATE, respectively. DAS28-ESR low disease activity (LDA) and remission (REM) rates were numerically higher in the CZP + MTX group than PBO + MTX group at weeks 12 and 24, across RF quartiles. LDA and REM rates in the CZP + MTX groups were comparable across RF quartiles at weeks 12 and 24. Mean DAS28-ESR decreased from week 0 to week 24 in the CZP + MTX groups, across RF quartiles. Conclusion: CZP showed steady efficacy across baseline RF quartiles in patients with early and established RA, over 24 weeks. CZP treatment may be considered in patients with RA irrespective of baseline RF levels and time from diagnosis.